Fatih URUÇ, Serkan AKAN, BEKİR ARAS, Özgür Haki YÜKSEL, Aytaç ŞAHİN, Ayhan VERİT

40 yaş altı mesane tümörlerinde orta dönem takip sonuçlarımız

Amaç: Ürotelyal tümörler genç hastalarda nadiren görülür. Bu nedenle genç hastalarda hastalığın doğal seyri ile ilgili bilgiler net değildir ve bu kategoride değerlendirilecek hastalar henüz tanımlanmamıştır. Çalışmamızda, küçük serilerimize dayanarak genç hastalarda görülen mesane tümörünün doğal seyrini öngörmeyi amaçladık. Gereç ve Yöntemler: Ocak 2012 ile Ocak 2017 arasında üroloji kliniğine başvuran 18- 40 yaşları arasındaki toplam 15 hasta geriye dönük olarak değerlendirildi. Olgularımız demografik veriler (yaş ve cinsiyet), sigara öyküsü, tümör tipi, grade, evre, odak sayısı, tümör rekürrensi ve intravezikal tedavi parameterleri değerlendirilerek 30 yaş altı ve 30-40 yaş aralığı olmak üzere iki ayrı gruba ayrılayarak analiz edildi Bulgular: Olgularımız 30 yaşın altındaki (n = 7; % 46.7) veya üzeri (n = 8; % 53.3) idi. Otuz yaşın altındaki düşük dereceli tümörlerin oranları 30 yaşın üzerindeki yaş grubuna göre daha yüksek bulundu (p: 0.007; p <0.01). Sonuç: Çalışmamızda, hastalar < 30 ve > 30 yaş hastalar olarak değerlendirildiğinde, yaş faktörünün, tümör boyutu, histopatolojik grade ve evre, intravezikal tedaviye verilen tedavi yanıtları ve tümör rekürrensi ile doğrudan korelasyona sahip potansiyel olarak negatif bir prediktif faktör olduğu gözlemlendi.

Anahtar Kelimeler:

Mesane tümörü, genç hasta, tümör rekürrensi

Our mid-term follow-up results in bladder tumors below 40 years of age

Purpose: Urothelial tumors are rarely seen in young patients. Therefore in these types of patients, information related to natural course of the disease are not clear-cut and patients who will be evaluated in the young age category have not been defined yet. In our study, based on our small series, we aimed to predict the natural course of the bladder tumor seen in young patients peculiar to this age group. Material and Methods: A total of 15 patients aged between 18-40 years who consulted to our urology clinic between January 2012 and January 2017 were retrospectively evaluated. Our cases were analyzed by demographic data (age and gender), smoking history, tumor type, grade, stage, number of foci, tumor recurrence and intravesical treatment parameters and dividing into two groups of under age 30 and age range 30-40 years. Results: Our cases were either below (n=7; 46.7 %) or above (n=8; 53.3 %) 30 years of age. The rates of low grade tumors in the age group of ≤ 30 years were found to be higher when compared with the age group of > 30 years (p:0.007; p<0.01). Conclusion: In our study, when patients were evaluated as those aged < 30 and > 30 years, age factor was observed to be a potentially negative predictive factor directly correlated with tumor size, histopathological grade and stage, treatment responses to intravesical therapy and tumor recurrence.

Keywords:

Bladder tumors, young patients, tumor recurrence,

PDF

___

1. Howlader N, Noone AM, Krapcho M. SEER Cancer Statistics Review, Bladder Section, 1975–2008. Bethesda, MD: National Cancer Institute.
2. Fine SW, Humphrey PA, Dehner LP, Amin MB, Epstein JI. Urothelial neoplasms in patients 20 years or younger: a clinicopathological analysis using the World Health Organization 2004 Bladder Consensus Classification. J Uro. 2005; 174:1976–80.
3. Migaldi M, Rossi G, Maiorana G, Sartori G, Ferrari P, De Gaetani C, et al. Superficial papillary urothelial carcinomas in young and elderly patients: a comparative study. BJU Int 2004; 94:311–6.
4. Yossepowitch O, Dalbagni G. Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome. J Urol 2002; 168:61–6.
5. Telli O, Sarici H, Ozgur BC, Doluoglu OG, Sunay MM, Bozkurt S, et al. Urothelial cancer of bladder in young versus older adults: clinical and pathological characteristics and outcomes. Kaohsiung J Med Sci 2014; 30:466-70.
6. Wen YC, Kuo JY, Chen KK, Lin AT, Chang YH, Hsu YS, et al. Urothelial carcinoma of the urinary bladder in young adults- Clinical experience at Taipei Veterans General Hospital. Journal of the Chinese Medical Association 2005;68:272-5.
7. Owen HC, Giedl J, Wild PJ, Fine SW, Humphrey PA, Dehner LP, et al. Low frequency of epigenetic events in urothelial tumors in young patients. J Urol 2010; 184:459–46.
8. Greenfield SP, Williot P, Kaplan D. Gross hematuria in children: a ten year review. Urology 2007; 69:166–9.
9. Mueller CM, Caporaso N, Greene MH. Familial and genetic risk of transitional cell carcinoma of the urinary tract. Urol Oncol 2008; 26:451–64.
10. Williamson SR, Wang M, Montironi R, Eble JN, Lopez- Beltran A, Zhang S, et al. Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. Mod Pathol 2014; 27:1540-8.
11. Paner GP, Zehnder P, Amin AM, Husain AN, Desai MM. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management. Adv Anat Patho. 2011; 18:79-89.
12. Lezama–del Valle P, Jerkins GR, Rao BN, Santana VM, Fuller C, Merchant TE. Aggressive bladder carcinoma in a child. Pediatr Blood Cancer 2004; 43:285–8.
13. Scott AA, Stanley W, Worsham GF, Kirkland TA Jr, Gansler T, Garvin AJ. Aggressive bladder carcinoma in an adolescent. Report of a case with immunohistochemical, cytogenetic, and flow cytometric characterization. Am J Surg Pathol 1989; 13:1057–63.